Antigen's modified cancer vaccine moves forward with IND filing
This article was originally published in Scrip
Executive Summary
Antigen Express, a subsidiary of Generex Biotechnology, has announced that a physician-sponsored IND has been submitted to the US FDA for its modified immunotherapeutic cancer vaccine, AE37 combined with a vaccine peptide, to enable a Phase I trial in breast and ovarian cancer to start.